Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (71-80 of 188) with videos related to

Pageof 19
Sort By:
Haematologica|April 22, 2017
Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myelomaIsabel J F Hofman, Stephanie Patchett, Mark van Duin, et al.
Cancer Treatment and Research Communications|May 7, 2021
Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine?Laura Yissel Rengifo, Sanne Smits, Lieselot Buedts, et al.
Therapeutic Advances in Hematology|June 26, 2025
Acquired von Willebrand syndrome secondary to monoclonal gammopathy: a single-center case seriesQuentin Van Thillo, Finn Segers, Jan Brijs, et al.
Haematologica|June 14, 2006
The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromesTheo de Witte, Ronald Brand, Anja van Biezen, et al.
European Journal of Haematology|April 4, 2012
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trialMichel Delforge, Ravinder Dhawan, Don Robinson, et al.
Blood Advances|December 21, 2021
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myelomaMichel Delforge, Nina Shah, Jesús San F Miguel, et al.
British Journal of Haematology|July 14, 2016
Multiple myeloma: patient outcomes in real-world practiceKwee Yong, Michel Delforge, Christoph Driessen, et al.
British Journal of Haematology|June 14, 2016
Multiple myeloma: practice patterns across EuropeMarc S Raab, Michele Cavo, Michel Delforge, et al.
Leukemia Research|April 23, 2023
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trialMichel Delforge, Paula Rodríguez Otero, Nina Shah, et al.
BMC Medical Informatics and Decision Making|November 28, 2025
Patients and healthcare professionals' perspectives on the implementation of shared decision making in multiple myeloma: a multinational qualitative studyElise Schoefs, Charlotte Verbeke, Jolien Broekmans, et al.
Pageof 19

Showing results (71-80 of 188) with videos related to

Sort By:
Pageof 19
Haematologica|April 22, 2017
Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myelomaIsabel J F Hofman, Stephanie Patchett, Mark van Duin, et al.
Cancer Treatment and Research Communications|May 7, 2021
Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine?Laura Yissel Rengifo, Sanne Smits, Lieselot Buedts, et al.
Therapeutic Advances in Hematology|June 26, 2025
Acquired von Willebrand syndrome secondary to monoclonal gammopathy: a single-center case seriesQuentin Van Thillo, Finn Segers, Jan Brijs, et al.
Haematologica|June 14, 2006
The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromesTheo de Witte, Ronald Brand, Anja van Biezen, et al.
European Journal of Haematology|April 4, 2012
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trialMichel Delforge, Ravinder Dhawan, Don Robinson, et al.
Blood Advances|December 21, 2021
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myelomaMichel Delforge, Nina Shah, Jesús San F Miguel, et al.
British Journal of Haematology|July 14, 2016
Multiple myeloma: patient outcomes in real-world practiceKwee Yong, Michel Delforge, Christoph Driessen, et al.
British Journal of Haematology|June 14, 2016
Multiple myeloma: practice patterns across EuropeMarc S Raab, Michele Cavo, Michel Delforge, et al.
Leukemia Research|April 23, 2023
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trialMichel Delforge, Paula Rodríguez Otero, Nina Shah, et al.
BMC Medical Informatics and Decision Making|November 28, 2025
Patients and healthcare professionals' perspectives on the implementation of shared decision making in multiple myeloma: a multinational qualitative studyElise Schoefs, Charlotte Verbeke, Jolien Broekmans, et al.
Pageof 19